Esperion Therapeutics Inc (ESPR) 100.53 $ESPR
Open Minded about Closed Offerings
M2 - Tue Apr 21, 8:44AM CDT
Considering that not long ago shareholders would run away the moment that a company announced a secondary offering, it's great to see that the greater investing public is often embracing this key expansionary tool. The standard operating procedure was to employ a static valuation model, based on the dilution compared to the company's current earnings. However, many investors are now also factoring in the company's reasonable future earnings potential into the equity valuation model.
ESPR: 100.53 (-2.60), CACC: 211.50 (+5.39), FISI: 24.02 (+0.49), BXMT: 31.24 (+0.04), VLTC: 15.14 (-1.04)
Critical Alerts For BlackBerry, Hasbro, Esperion Therapeutics, Chesapeake Energy and OmniVision Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, HAS, ESPR, CHK and OVTI.
HAS: 71.73 (-1.82), ESPR: 100.53 (-2.60), CHK: 14.41 (-0.16), BBRY: 9.92 (-0.11), OVTI: 26.82 (+0.26)
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), RCPT: 166.76 (-3.37)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 100.53 (-2.60), AZN: 73.35 (+0.65), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), EGRX: 60.53 (+1.22), HPTX: 45.96 (-0.18)
The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 100.53 (-2.60), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Esperion Therapeutics to Present at 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 14th Annual Needham Healthcare Conference in New York City on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time.
ESPR: 100.53 (-2.60)
Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT
OXGN: 1.49 (-0.02), TRVN: 6.91 (-0.53), ESPR: 100.53 (-2.60), OVAS: 29.85 (-0.24), UHS: 121.07 (+0.12), NLNK: 53.12 (-0.07), RTRX: 24.45 (+0.09), SYK: 96.45 (+1.74)
Here's How Esperion Therapeutics, Inc. Could Get to $140
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 01, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Esperion Therapeutics , a clinical-stage...
ESPR: 100.53 (-2.60)
Esperion Up As UBS Touts Cholesterol Drug
at Investor's Business Daily - Wed Apr 01, 2:44PM CDT
Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a...
ESPR: 100.53 (-2.60), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), ESPR: 100.53 (-2.60), ACAD: 38.55 (-0.20), BMRN: 121.08 (-0.16), ICEL: 16.47 (-0.02), UNH: 117.81 (-1.47), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), ABBV: 64.52 (+0.91), HPTX: 45.96 (-0.18)
3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 100.53 (-2.60), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
First Week of May 15th Options Trading For Esperion Therapeutics (ESPR)
DividendChannel.com - Fri Mar 27, 9:53AM CDT
Investors in Esperion Therapeutics Inc saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ESPR options chain for the new May 15th contracts and...
ESPR: 100.53 (-2.60)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.88 (+0.03), ESPR: 100.53 (-2.60), NVAX: 8.51 (+0.09), PFE: 34.93 (+0.04), XON: 44.53 (+0.36)
Why Esperion Therapeutics, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 12:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics ...
ESPR: 100.53 (-2.60)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)
Weakness Seen in Esperion Therapeutics (ESPR): Stock Tumbles 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:39AM CDT
Make sure to keep an eye on Esperion Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
ESPR: 100.53 (-2.60)
Esperion closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:58PM CDT
ESPR: 100.53 (-2.60)
Open Minded about Closed Offerings
M2 - Tue Apr 21, 8:44AM CDT
Considering that not long ago shareholders would run away the moment that a company announced a secondary offering, it's great to see that the greater investing public is often embracing this key expansionary tool. The standard operating procedure was to employ a static valuation model, based on the dilution compared to the company's current earnings. However, many investors are now also factoring in the company's reasonable future earnings potential into the equity valuation model.
ESPR: 100.53 (-2.60), CACC: 211.50 (+5.39), FISI: 24.02 (+0.49), BXMT: 31.24 (+0.04), VLTC: 15.14 (-1.04)
Critical Alerts For BlackBerry, Hasbro, Esperion Therapeutics, Chesapeake Energy and OmniVision Released By InvestorsObserver
PR Newswire - Tue Apr 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBRY, HAS, ESPR, CHK and OVTI.
HAS: 71.73 (-1.82), ESPR: 100.53 (-2.60), CHK: 14.41 (-0.16), BBRY: 9.92 (-0.11), OVTI: 26.82 (+0.26)
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), RCPT: 166.76 (-3.37)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 100.53 (-2.60), AZN: 73.35 (+0.65), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), EGRX: 60.53 (+1.22), HPTX: 45.96 (-0.18)
The 3 Best Stocks for Investing in Cholesterol Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 10:04AM CDT
Statins' cholesterol-lowering ability and a growing global need for cholesterol-busting treatment have turned statins into some of the most widely-prescribed drugs in the world. But until recently, investors hoping to profit from the billions of...
ESPR: 100.53 (-2.60), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Esperion Therapeutics to Present at 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 3:30PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 14th Annual Needham Healthcare Conference in New York City on Tuesday, April 14, 2015 at 1:40 p.m. Eastern Time.
ESPR: 100.53 (-2.60)
Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT
OXGN: 1.49 (-0.02), TRVN: 6.91 (-0.53), ESPR: 100.53 (-2.60), OVAS: 29.85 (-0.24), UHS: 121.07 (+0.12), NLNK: 53.12 (-0.07), RTRX: 24.45 (+0.09), SYK: 96.45 (+1.74)
Here's How Esperion Therapeutics, Inc. Could Get to $140
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 01, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Esperion Therapeutics , a clinical-stage...
ESPR: 100.53 (-2.60)
Esperion Up As UBS Touts Cholesterol Drug
at Investor's Business Daily - Wed Apr 01, 2:44PM CDT
Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a...
ESPR: 100.53 (-2.60), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), FMI: 48.71 (-0.96), ANTH: 4.79 (+0.10), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), TRIL: 20.67 (-2.53)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), ESPR: 100.53 (-2.60), ACAD: 38.55 (-0.20), BMRN: 121.08 (-0.16), ICEL: 16.47 (-0.02), UNH: 117.81 (-1.47), HZNP: 30.96 (+0.10), TEVA: 63.01 (-1.15), ASPX: 100.79 (+0.09), ABBV: 64.52 (+0.91), HPTX: 45.96 (-0.18)
3 Little-Known Biotechs Working On Potential Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 12:08PM CDT
Biotech stocks are prone to jaw-dropping pops and drops, caused by even the hint of positive or negative news surrounding drugs in their pipelines. That makes biotech one of the riskiest industries for investors. However, for those willing to take on...
ESPR: 100.53 (-2.60), PFE: 34.93 (+0.04), OPHT: 52.35 (+1.09), PRTA: 36.96 (+0.36), REGN: 472.63 (+9.41), NVS: 103.45 (-0.62)
First Week of May 15th Options Trading For Esperion Therapeutics (ESPR)
DividendChannel.com - Fri Mar 27, 9:53AM CDT
Investors in Esperion Therapeutics Inc saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ESPR options chain for the new May 15th contracts and...
ESPR: 100.53 (-2.60)
3 Biotech Stocks That Dropped Yesterday -- Is 1 a Buy?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 26, 7:31AM CDT
The biotech stock bubble got a bit deflated this week as the biotech industry ETF tumbled more than 4% on Wednesday. The drop-off in share prices was widespread across the industry, but some stocks were punished more than others. Among those that...
ZIOP: 10.88 (+0.03), ESPR: 100.53 (-2.60), NVAX: 8.51 (+0.09), PFE: 34.93 (+0.04), XON: 44.53 (+0.36)
Why Esperion Therapeutics, Inc. Shares Burst Today.
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 25, 12:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Esperion Therapeutics ...
ESPR: 100.53 (-2.60)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT
TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)
Weakness Seen in Esperion Therapeutics (ESPR): Stock Tumbles 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:39AM CDT
Make sure to keep an eye on Esperion Therapeutics going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
ESPR: 100.53 (-2.60)
Esperion closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:58PM CDT
ESPR: 100.53 (-2.60)
